Hulyo 2022: Ayon sa pinakahuling pananaliksik na isinagawa ng Emergen Research, ang pandaigdigang merkado para sa CAR T-cells therapy ay umabot sa laki na USD 1.29 bilyon noong 2021 at inaasahang magrehistro ng isang kita na CAGR na 24.9 porsyento sa kurso ng panahon ng pagtataya. Ang tumataas na saklaw ng kanser sa buong mundo pati na rin ang lumalagong rate ng namamatay na sanhi ng cancer ay inaasahan na maging pangunahing mga driver ng paglago ng kita sa pandaigdigang CAR-T cell therapy market sa paglipas ng panahon ng pagtataya. Ang pagpapalawak ng mga aktibidad sa klinikal na pagsubok sa isang napakabilis na bilis, ang paglaganap ng mga pagsasanib at pagkuha, at ang pag-akit ng mga paunang pampublikong alok ay lahat ng mga kadahilanan na nag-aambag sa paglago ng kita sa pandaigdigang merkado ng CAR T-cell therapy.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-Cell Therapy market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-Cell Therapy market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Ang mga karagdagang makabuluhang natuklasan mula sa ulat ay nagpapahiwatig na
Sa 2021, ang segment ng nagkakalat na malaking B-cell lymphoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimeric antigen receptor T-cell therapy, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell mga non-Hodgkin lymphoma who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Ang mga pangunahing kumpanya na kasalukuyang tumatakbo sa merkado ay sinisiyasat pa sa ulat na ito, pati na rin ang kanilang mga profile ng kumpanya, mga portfolio ng produkto, mga diskarte sa pagpapalawak, at mga estratehikong alyansa. Ang ilang halimbawa ng mga ganitong uri ng alyansa ay kinabibilangan ng mga merger at acquisition, pakikipagtulungan, at joint venture. Bilang karagdagan dito, nagbibigay ito ng mga highlight tungkol sa mga nagawa ng kumpanya at katayuan sa pananalapi, pati na rin ang mga insight sa abot ng merkado at pandaigdigang posisyon ng kumpanya.
Mga kumpanyang naka-profile sa pandaigdigang CAR T-Cell Therapy market:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., at Eli Lilly and Company .
Magbasa nang higit pa sa pandaigdigang ulat ng merkado ng CAR T-Cell Therapy sa: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
